Endpoint Health

endpointhealth.com →

-88%

est. 2Y upside i

HealthcareSeries A

Precision-first therapies

Rank

#3674

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Given the stale valuation and missing growth data, the expected 2-year equity upside is strongly negative at -88%.

Last updated: July 3, 2026

Bull (10%)-40%

If an IPO window opens and the company achieves category leadership, the exit multiple could expand to 12x projected revenue of $12M, yielding an exit value of $144M. After 20% dilution, upside is -40%.

Base (52%)-80%

With no special catalysts, the exit multiple converges to the public comp range of 6x projected revenue of $12M, resulting in an exit value of $72M. After 20% dilution, upside is -80%.

Bear (38%)-100%

If the market compresses to 3x revenue ($36M exit) or below, the preference stack of $64M ensures common stock recovers nothing, leading to a -100% loss.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

3560%

Total funding of $64M is 35.6% of the estimated entry valuation, indicating severe preference overhang.

Dilution Risk

high

Last round was in 2022, and given high capital intensity, a significant fundraise within 24 months is likely, resulting in 15-25% dilution.

Secondary Liquidity

none

No secondary market data available; employee equity likely illiquid until a liquidity event.

Questions to Ask at the Interview

Strategic questions based on Endpoint Health's data — designed to show you've done your homework.

  • 1

    “How does the company plan to bridge the gap between current revenue and the high valuation implied by the 2022 round?”

  • 2

    “What are the specific milestones for the therapeutic pipeline and companion diagnostics in the next 24 months?”

  • 3

    “Given the preference stack overhang, what is the expected dilution in future rounds and how does that impact employee equity?”

Community

Valuation Sentiment

Our model estimates -88% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.